Quantification of muscle pathology in infantile Pompe disease
- PMID: 27927596
- DOI: 10.1016/j.nmd.2016.10.010
Quantification of muscle pathology in infantile Pompe disease
Abstract
The effects of enzyme replacement therapy (ERT) in infantile Pompe disease are variable, necessitating the identification of biomarkers to assess the severity of disease and response to ERT. The aims of this study were to investigate whether quantification of muscle pathology in infantile Pompe disease prior to and during ERT is feasible at the light microscope, and to develop a score that summarizes the degree of muscle pathology in a comprehensive manner from PAS-stained resin sections alone. We, therefore, determined glycogen load, extent of muscle fibre disruption, and amount of autophagic vacuoles in resin-embedded muscle biopsy specimens from 11 infantile Pompe patients and 2 with early childhood phenotype by quantitative methods, correlated the findings with ultrastructural analyses, compared PAS-stained resin sections with conventional PAS-stained cryosections, and related the quantified degree of muscle damage from infantile patients to the effects of ERT. Comparison of electron and light microscopic findings demonstrated that important alterations of skeletal muscle morphology can also be depicted by examining PAS stained resin sections. Infantile patients with good response to ERT had lower muscle pathology score values prior to and during ERT than those with moderate and poor response, but the number of tissue samples available for evaluation was limited. These findings suggest that quantification of muscle pathology by analysing PAS stained resin sections is in principle feasible and useful to monitor disease progression and therapy response. These results have to be validated by investigating a larger group of patients.
Keywords: Acid maltase deficiency; Autophagy; Enzyme replacement therapy; Glycogen storage disease type II; Lysosomal storage disease; Pompe disease.
Copyright © 2016 Elsevier B.V. All rights reserved.
Similar articles
-
Infantile Pompe disease on ERT: update on clinical presentation, musculoskeletal management, and exercise considerations.Am J Med Genet C Semin Med Genet. 2012 Feb 15;160C(1):69-79. doi: 10.1002/ajmg.c.31321. Epub 2012 Jan 17. Am J Med Genet C Semin Med Genet. 2012. PMID: 22252989 Review.
-
Prospective exploratory muscle biopsy, imaging, and functional assessment in patients with late-onset Pompe disease treated with alglucosidase alfa: The EMBASSY Study.Mol Genet Metab. 2016 Sep;119(1-2):115-23. doi: 10.1016/j.ymgme.2016.05.013. Epub 2016 May 19. Mol Genet Metab. 2016. PMID: 27473031 Clinical Trial.
-
Skeletal muscle pathology of infantile Pompe disease during long-term enzyme replacement therapy.Orphanet J Rare Dis. 2013 Jun 20;8:90. doi: 10.1186/1750-1172-8-90. Orphanet J Rare Dis. 2013. PMID: 23787031 Free PMC article.
-
Effects of short-to-long term enzyme replacement therapy (ERT) on skeletal muscle tissue in late onset Pompe disease (LOPD).Neuropathol Appl Neurobiol. 2018 Aug;44(5):449-462. doi: 10.1111/nan.12414. Epub 2017 Jul 4. Neuropathol Appl Neurobiol. 2018. PMID: 28574618
-
Autophagy in skeletal muscle: implications for Pompe disease.Int J Clin Pharmacol Ther. 2009;47 Suppl 1(Suppl 1):S42-7. doi: 10.5414/cpp47042. Int J Clin Pharmacol Ther. 2009. PMID: 20040311 Free PMC article. Review.
Cited by
-
Letter to the Editors: Concerning "Divergent clinical outcomes of alpha-glucosidase enzyme replacement therapy in two siblings with infantile-onset Pompe disease treated in the symptomatic or pre-symptomatic state" by Takashi et al. and Letter to the Editors by Ortolano et al.Mol Genet Metab Rep. 2017 May 16;12:33-34. doi: 10.1016/j.ymgmr.2017.05.005. eCollection 2017 Sep. Mol Genet Metab Rep. 2017. PMID: 28560178 Free PMC article. No abstract available.
-
Dysregulation of Metabolism and Proteostasis in Skeletal Muscle of a Presymptomatic Pompe Mouse Model.Cells. 2023 Jun 11;12(12):1602. doi: 10.3390/cells12121602. Cells. 2023. PMID: 37371072 Free PMC article.
-
Long-term outcome and unmet needs in infantile-onset Pompe disease.Ann Transl Med. 2019 Jul;7(13):283. doi: 10.21037/atm.2019.04.70. Ann Transl Med. 2019. PMID: 31392195 Free PMC article. Review.
-
Follow-up of late-onset Pompe disease patients with muscle magnetic resonance imaging reveals increase in fat replacement in skeletal muscles.J Cachexia Sarcopenia Muscle. 2020 Aug;11(4):1032-1046. doi: 10.1002/jcsm.12555. Epub 2020 Mar 4. J Cachexia Sarcopenia Muscle. 2020. PMID: 32129012 Free PMC article.
-
Rat models of musculoskeletal lysosomal storage disorders and their role in pre-clinical evaluation of gene therapy approaches.Mamm Genome. 2025 Jun;36(2):488-499. doi: 10.1007/s00335-025-10121-3. Epub 2025 Mar 18. Mamm Genome. 2025. PMID: 40100425 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous